The USFDA conducted an inspection of Cohance’s manufacturing facility located at Pashamylaram in Hyderabad between July 27 and August 5, 2026. At the conclusion of the inspection, the regulator issued a Form 483 listing observations identified during the review.
A Form 483 is issued by the USFDA when inspectors identify potential areas of concern during a facility inspection. The observations are shared with the company to allow it to review the issues and submit a response, including corrective and preventive actions, where required.
Cohance Lifesciences said that none of the observations issued by the regulator relate to data integrity issues, a key area of focus in pharmaceutical manufacturing compliance.
Company preparing response
The company said it is conducting a detailed assessment of the observations raised by the USFDA and is preparing a comprehensive response.
Cohance added that its submission will include appropriate corrective and preventive actions (CAPAs) and will be filed within the timeline prescribed by the regulator.
Corrective and preventive actions are measures taken by pharmaceutical companies to address identified quality concerns, prevent recurrence and strengthen manufacturing processes. These may include improvements to procedures, documentation practices, training systems or operational controls, depending on the nature of the observations.
The company said it remains committed to maintaining high standards of quality and regulatory compliance across its manufacturing operations.
Cohance added that the observations are addressable and that it will continue to engage with the USFDA to ensure timely and effective resolution.
Regulatory compliance remains key for pharma companies
Regulatory inspections are a routine part of pharmaceutical manufacturing, particularly for companies supplying products to regulated markets such as the United States. Compliance with USFDA standards is important as regulatory clearances can influence a company’s ability to manufacture and supply products to global customers.
Pharmaceutical companies typically work with regulators after inspections to address observations and strengthen quality systems. The issuance of a Form 483 itself does not represent a final regulatory action, but companies are expected to provide satisfactory responses and implement necessary improvements.
For contract development and manufacturing companies, maintaining regulatory compliance is particularly important as global pharmaceutical customers rely on their manufacturing partners to meet stringent quality standards.
Cohance Lifesciences, which operates in the life sciences sector, has manufacturing capabilities focused on pharmaceutical ingredients and related products. The company said it will continue its efforts towards maintaining compliance across its facilities.
Shares of Cohance Lifesciences closed 0.82% higher at ₹428.40 on the NSE on August 5.
